Mono Antiplatelet and Colchicine Therapy

• Status: Recruiting
• Trial end date: 2022-06-13
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of aspirin-free, P2Y12 inhibitor single antiplatelet and colchicine treatment in patients with acute coronary syndrome treated with drug-eluting stents.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wonkwang University Hospital
• Treatments: Aspirin; Colchicine

Criteria

Inclusion Criteria:

• Successful PCI with drug-eluting stent for NSTE-ACS or STEMI

• Provision of written informed consent

Exclusion Criteria:

• Cardiac arrest or cardiogenic shock

• Age <19 or >90 years old

• Severe liver impairment

• Severe renal impairment (eGFR <30 mL/min/1.73 m2)

• Intolerance of prasugrel, ticagrelor, or colchicine

• History of intracranial hemorrhage

• Active bleeding